Group 1 - Postal Savings Bank plans to invest 10 billion yuan to establish China Post Financial Asset Investment Co., with a registered capital of 10 billion yuan, aiming to enhance comprehensive service capabilities and support technological innovation and private enterprises [1] - Tuo Xin Pharmaceutical intends to increase capital by 10 million yuan in Jiangsu Jin San Biotechnology Co., acquiring a 1.75% stake, with Jin San successfully producing high-purity ergothioneine for various products [2] - Anker Innovations is researching overseas share issuance to expand its global strategy and enhance brand influence, with no specific plan confirmed yet [3] Group 2 - Hoshine Silicon Industry's controlling shareholder plans to transfer 5.08% of shares to Xiao Xiugan for a total price of 2.634 billion yuan, with no change in control [4] - Zhuhai Guanyu has won a final ruling from the Supreme People's Court, dismissing the lawsuit from ATL, with 14 ATL patents declared invalid and no negative impact on the company's operations [5] - Lixing Co. has terminated the acquisition of Qingdao Feiyan Precision Steel Ball Manufacturing Co. due to failure to reach an agreement, with no adverse effects on its financial status [6] Group 3 - Pinming Technology expects a net profit of 28 million to 34 million yuan for the first half of the year, representing a year-on-year increase of 231.79% to 302.89% [7] - Tiande Yu's performance report anticipates a net profit of 152 million yuan for the first half, up 50.89% year-on-year [7] - Huahong Technology reports normal operations with no undisclosed significant matters [8]

Core Viewpoint - Toxin Pharmaceutical (301089.SZ) announced an investment of 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, aiming to leverage its technological advantages in the field of chemical and synthetic biology [1] Group 1: Investment Details - The investment consists of 223,400 yuan added to registered capital, with the remainder allocated to capital reserves [1] - Following the investment, Toxin Pharmaceutical will hold a direct stake of 1.75% in Jinsan Biotechnology [1] Group 2: Company Overview - Jinsan Biotechnology specializes in the research, production, and sales of synthetic biological products, focusing on the development and industrial application of ergothioneine [1] - The company has achieved breakthroughs in the entire chain of technology, including strain construction, fermentation, purification, and engineering-scale production of high-purity ergothioneine [1] Group 3: Market Potential - The market for ergothioneine terminal products in China is projected to reach 1.57 billion yuan by 2024, with 60% used in skincare and nearly 30% in health food [3] - The global ergothioneine raw material market is expected to grow from 6.3 million USD in 2024 to 16.1 million USD by 2031, with a CAGR exceeding 14% [3] Group 4: Controversies - Ergothioneine has faced controversies, including claims by a prominent biologist labeling it as a "fake drug," which has been disputed by related companies citing scientific backing [4]

Group 1 - Meidi Technology plans to acquire 100% equity of Haisholi and INNOWAVE VIETNAM for a total of 2 billion KRW, which is approximately 219.47 million USD, allowing direct entry into Samsung's supply chain [3] - Toxin Pharmaceutical will increase its investment in Jiangsu Jinsan Biotechnology by 10 million CNY, acquiring a 1.75% stake, as Jinsan has successfully produced high-purity ergot sulfur [4] - Zhejiang Energy Power reported a power generation of 78.848 billion kWh in the first half of the year, a year-on-year increase of 4.48%, attributed to increased electricity demand in Zhejiang province [5] Group 2 - Tiande Yu expects a net profit of 152 million CNY for the first half of 2025, a year-on-year increase of 50.89%, driven by the growth in high-refresh-rate mobile display driver chips [7] - Pinming Technology anticipates a net profit increase of 231.79% to 302.89% for the first half of 2025, due to growth in building information software revenue and effective cost control [8] - *ST Jinglun expects a loss of 19 to 22 million CNY in the first half of 2025, despite a 23.5% increase in revenue to approximately 83 million CNY, as overall gross profit is insufficient to cover expenses [9] Group 3 - Jindi Co. signed an industrial project investment contract with the government of Bishan District, with a total investment of no less than 1.5 billion CNY [11] - Baiyun Electric is expected to win a procurement project from the State Grid worth 164 million CNY, which represents 3.28% of the company's audited revenue for 2024 [13] Group 4 - Fulei New Materials' shareholder plans to reduce its stake by up to 1.33%, amounting to a maximum of 3.7625 million shares [15] - Wind God Co. plans to raise no more than 1.1 billion CNY through a private placement for a project aimed at enhancing the capacity and efficiency of high-performance giant engineering tires [17]

Group 1 - Tiande Yu achieved a net profit of 1.52 billion yuan in the first half of 2025, a year-on-year increase of 50.89% [1] - Tiande Yu's operating income for the same period was 12.08 billion yuan, reflecting a growth of 43.35% year-on-year [1] - Fule New Materials plans to reduce its shareholding by up to 1.33%, amounting to 376.25 million shares, due to personal funding needs [1] - Jindi Co. signed an industrial project investment contract with a total investment of no less than 1.5 billion yuan [1] Group 2 - Tuo Xin Pharmaceutical intends to invest 10 million yuan in Jiangsu Jinsan Biotechnology, acquiring a 1.75% stake [1] - Pinming Technology expects a net profit of 28 million to 34 million yuan for the first half of 2025, a year-on-year increase of 231.79% to 302.89% [4] - Shuanglin Co. anticipates a net profit of 251 million to 310 million yuan, representing a growth of 1% to 25% year-on-year [7] Group 3 - Kangxino received approval for clinical trials of its trivalent poliovirus vaccine [8] - Bailian Co. signed a land storage compensation contract worth approximately 2 billion yuan [9] - Wukuang Development plans to issue short-term financing bonds and medium-term notes totaling up to 2 billion yuan each [10] Group 4 - Hengxin Life intends to invest 10 million yuan in a targeted equity investment [12] - Hengyin Technology expects a net profit of 13.5 million to 16.2 million yuan, marking a turnaround from losses [14] - *ST Jinglun anticipates a net loss of 19 million to 22 million yuan for the first half of 2025 [15] Group 5 - Baiyun Electric won a bid for a State Grid project worth 164 million yuan [16] - Zhejiang Energy completed a power generation of 788.48 billion kWh in the first half of 2025, a year-on-year increase of 4.48% [17] - Sheneng Co. reported a power generation of 259.51 billion kWh, a decrease of 1.7% year-on-year [19] Group 6 - Hengerd signed a strategic cooperation framework agreement with Tiangong International [21] - Baotai's application for the listing of Golimumab injection has been accepted by the FDA [23] - Yishitong received a government subsidy of 2 million yuan [24] Group 7 - Jinggong Steel signed a contract worth approximately 550 million yuan for the Jeddah Stadium project in Saudi Arabia [26] - Zhongwang Software received a government subsidy of 28 million yuan [27] - Rongxin Culture used idle funds of 100 million yuan to purchase financial products [29] Group 8 - Lingxiao Pump Industry invested 80 million yuan in financial products [31] - China Pacific Insurance reported a total original insurance premium income of 282 billion yuan from its subsidiaries [32] - Kema Technology expects a net profit of 165 million to 175 million yuan, a year-on-year increase of 18.59% to 25.77% [32] Group 9 - Qujiang Cultural Tourism anticipates a net loss of approximately 13 million to 16.9 million yuan [32] - Daoshi Technology expects a net profit of 220 million to 238 million yuan, a year-on-year increase of 98.77% to 115.03% [32] - Baicheng Medicine forecasts a net profit decline of 95.53% to 100% [33] Group 10 - Bertley plans to invest 198 million yuan to establish a partnership for investments in emerging fields [34] - China Merchants Highway announced the resignation of its chairman due to reaching retirement age [35] - Overseas Chinese Town A reported a 29% decrease in contract sales amount in June [36]

Core Viewpoint - Toxin Pharmaceutical (301089.SZ) plans to invest 10 million yuan in Jiangsu Jiansan Biotechnology Co., Ltd. (referred to as "Jiansan Biotechnology") to acquire a 1.75% stake in the company, which has successfully developed high-purity ergothioneine [1] Group 1 - Toxin Pharmaceutical will use its own funds for the investment of 10 million yuan [1] - After the investment, Toxin Pharmaceutical will directly hold 1.75% of Jiansan Biotechnology's equity [1] - Jiansan Biotechnology has achieved the production of high-purity ergothioneine, with main products including ergothioneine skincare products, oral capsules, and eye wash solutions [1]

拓新药业集团股份有限公司 第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 拓新药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会 议通知于 2025 年 7 月 12 日以电话、邮件等方式向各位董事发出，会议于 2025 年 7 月 15 日以现场会议结合通讯形式在公司会议室召开。本次会议由公司董事 长杨西宁先生召集并主持，实际出席会议的董事 9 人，其中以通讯形式出席会 议的董事 2 人，分别为咸生林、王秀强，公司监事及其他高级管理人员列席了 会议。 本次会议的召集、召开及表决符合《中华人民共和国公司法》及《拓新药 业集团股份有限公司章程》（以下简称《公司章程》）的有关规定，会议合法 有效。 二、董事会会议审议情况 1、审议通过《关于对外投资的议案》 证券代码：301089 证券简称：拓新药业 公告编号：2025-033 表决结果：9 票赞成，0 票反对，0 票弃权。 三、备查文件 1、《拓新药业集团股份有限公司第五届董事会第六次会议决议》 1 特此公告。 拓新药业集团股份有限公司 董事会 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-034 拓新药业集团股份有限公司 关于对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、对外投资概述 拓新药业集团股份有限公司（以下简称"公司"或"拓新药业"）在 2025 年 7 月 15 日召开第五届董事会第六次会议，会议审议通过了《关于对外投资的 议案》，公司将以自有资金 1,000 万元人民币对江苏仅三生物科技有限公司（以 下简称"仅三生物"或"目标公司"）进行增资，其中 22.3377 万元计入注册资 本，剩余部分计入资本公积。公司与仅三生物签署《关于江苏仅三生物科技有限 公司之增资协议》（以下简称"《增资协议》"），本次交易完成后，拓新药业 将直接持有仅三生物 1.75%的股权（最终以市场监督管理部门变更登记为准）。 二 、审议程序履行情况 公司于 2025 年 7 月 15 日召开的第五届董事会第六次会议审议通过了《关于 对外投资的议案》。根据《深圳证券交易所创业板股票上市规则》《公司章程》 等相关规定，本次对外投资事项在公司董事会决策权限范围内，无需提交公司股 ...

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with PCB, CRO, and consumer electronics outsourcing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. PCB Sector - PCB concept stocks continued to strengthen, with International Composite Materials and Yidong Electronics hitting the 20% daily limit up. Jin'an Guoji achieved a four-day consecutive rise, while Honghe Technology had four limit-up days in six days [8][9]. Pharmaceutical Sector - The pharmaceutical sector was notably strong, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Lianhuan Pharmaceutical achieved a consecutive limit-up, while companies like Weixin Kang, Hasan Lian, and Xiaofang Pharmaceutical also hit the limit-up. Toxin Pharmaceutical and Ruizhi Pharmaceutical saw increases exceeding 10% [4][5][6]. Notable Stock Movements - Fujilai (301258) surged to a limit-up of 20.01%, reaching a price of 39.28 CNY per share shortly after opening. Other notable stocks included Tuoxin Pharmaceutical and Ruizhi Pharmaceutical, which rose by 13.27% and 12.88%, respectively [5][6]. Regulatory Issues - Ruiskanda faced a trading halt due to a 9.95% drop, attributed to regulatory issues involving its chairman and director, who are under criminal coercive measures for alleged violations related to information disclosure. The company had previously faced administrative penalties from the CSRC [11][13].

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with circuit board, CRO, and consumer electronics manufacturing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. Pharmaceutical Sector - The pharmaceutical sector experienced a strong opening, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Notable stocks included Lianhuan Pharmaceutical, which achieved a two-day limit up, and several others like Weixin Kang and Ha Sanlian hitting the daily limit [7][8]. - Fujilai (301258) surged to a limit up of 20% to reach a price of 39.28 CNY per share shortly after the market opened [8][9]. PCB Sector - PCB (Printed Circuit Board) stocks continued to strengthen, with companies like International Composite Materials and Yidong Electronics hitting the daily limit. Jin'an Guoji achieved a four-day limit up, while Honghe Technology recorded four limit ups in six days [12][13]. - The demand for high-end PCBs is rapidly increasing due to AI computing needs, leading to a significant supply-demand gap in AI PCBs this year. ASIC chip growth is expected to be the main driver of incremental demand for high-end PCBs by 2026 [14][15]. Company-Specific News - Ruisi Kanda faced a trading halt with a limit down of 9.95% due to allegations of information disclosure violations, leading to criminal measures against its executives [17][20]. - ST Huaming also experienced a limit down of 20.03% following administrative penalties for false disclosures in its financial reports [20].

Core Viewpoint - The approval of the raw material drug cytidine diphosphate choline by the National Medical Products Administration marks a significant milestone for the company, enhancing its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Xinxiang Pharmaceutical, received the "Approval Notification for Chemical Raw Material Drug Listing Application" for cytidine diphosphate choline [1] - This approval indicates that the product meets national drug review technical standards and has passed GMP compliance checks [1] Group 2: Product Significance - Cytidine diphosphate choline is commonly used as a neuroprotective agent and brain metabolism activator, with its core pharmacological action being the improvement of brain function and promotion of nerve repair [1] - The clinical application range includes patients with brain injuries, cerebrovascular diseases, and neurodegenerative diseases [1] Group 3: Market Impact - The approval will effectively broaden the company's product line and enhance its market competitiveness in the active pharmaceutical ingredient sector [1]